false 0001603207 0001603207 2024-04-08 2024-04-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares





Washington, DC 20549





Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): April 8, 2024



(Exact name of registrant as specified in charter)



Israel   001-36581   Not Applicable

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)

320 Hatch Drive    
Foster City, California       94404
(Address of principal executive offices)       (Zip Code)



Registrant’s telephone number, including area code: (415) 851-2410



(Former name or former address, if changed since last report)


Securities registered or to be registered pursuant to Section 12(b) of the Act:


Title of each class  



  Name of each exchange on which registered
Ordinary Shares, par value NIS 0.35 each   NTBL   The Nasdaq Capital Market


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 8.01 Other Events.


On April 8, 2024, Notable Labs, Ltd. (the “Company”) issued a press release regarding the presentation of data related to innovations in the use of cryopreserved samples in the Company’s Predictive Precision Medicine Platform (PPMP) assay at the American Association for Cancer Research (AACR 2024) conference being held in San Diego, California. A copy of the press release is filed herewith as Exhibit 99.1.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits


99.1   Press Release issued April 8, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: April 8, 2024 By: /s/ Thomas A. Bock
      Name: Thomas A. Bock
Title: Chief Executive Officer



EX-99.1 2 ex99-1.htm


Exhibit 99.1



Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at AACR 2024 Expands the Potential of the Platform


FOSTER CITY, CA, April 8, 2024 – Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented data related to innovations in the use of cryopreserved samples in the PPMP assay at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 2548).


“We are very pleased to share the result of our innovative sample handling study with the cancer community at AACR 2024. The ability to derive a high-quality assessment of the response to treatment based on the results of cryopreserved samples is an important innovation. It has been previously thought that frozen samples could not be effectively thawed and used for cell viability assays. Based on the data presented at AACR, Notable now has the potential to develop partnerships to assess new treatment regimens, including combination therapies, using Notable’s PPMP platform and archived, cryopreserved samples thawed according to our protocols and proprietary media compositions,” said Thomas Bock, M.D., Chief Executive Officer of Notable. “We hope this opens new opportunities to apply our PPMP to a broad range of archived samples and therapeutics to unlock value and new treatment options for patients with cancer.”


Joseph Wagner, Ph.D., Chief Scientific Officer of Notable, added, “As we are ready to initiate the Phase 2 program with volasertib in Q2 2024, we are dedicated to maintaining a focus on innovation for our PPMP. The careful evaluation of sample handling protocols, presented at AACR 2024, makes our PPMP more comprehensive and enhances the opportunity to study and apply it more broadly. As we continue to execute, we look forward to further demonstrating the potential of PPMP and partner with biopharmaceutical companies and innovators to provide potential new treatment options for patients with cancer.”


Summary of Data and Findings for Notable’s Sample Handling Study:


Overview: The study was designed to evaluate the potential use of cryopreserved samples as an alternative to fresh samples for predicting treatment response in acute myeloid leukemia (AML) using Notable’s PPMP.


Cryopreserved samples are known for exhibiting low sample viability and cell recovery, rendering their practical utilization challenging
Notable adapted an existing methodology to process cryopreserved patient-derived leukemia cells to investigate their use as an alternative to fresh samples in the PPMP assay


Method: First, a method was established using freshly isolated white blood cells (WBCs) from AML patients (<2 days from sample collection). A fraction of these cells was cryopreserved. Both fresh and cryopreserved cells (after thawing and culturing) were assessed on the PPMP and results compared. Second, the established method was applied to cryopreserved samples (from a biobank) collected from AML patients prior to their treatment with chemotherapy (cytarabine plus idarubicin). Results obtained on the PPMP were compared to the clinical responses experienced by the patients after treatment with cytarabine and idarubicin.





Results: For the method development study, ex vivo responses to 3 different compounds (venetoclax, 5-azacytidine and decitabine) were assessed after culturing of the cryopreserved cells for 24- and 48-hour post thaw using two different media (“A” and “B”). There was a strong correlation (R2 from 0.77 to 0.92) for venetoclax and 5-azacytidine between the results obtained with fresh vs. frozen samples. For the biobank samples treated with cytarabine and idarubicin, culture media A and B show a similar dose-response behavior. Importantly, the PPMP correctly predicted clinical responders (complete remission) and non-responders (refractory).


While Notable will continue to evaluate and validate these sample handling methodologies, these data open the door to the use of cryopreserved samples from retrospective cohorts.


Poster information: Retrospective prediction of clinical response to standard-of-care therapies in acute myeloid leukemia by an ex vivo drug sensitivity assay using cryopreserved primary samples


Session Category:   Clinical Research
Session Title:   Real-World Biomarkers
Session Date and Time:   Monday Apr 8, 2024 9:00 AM - 12:30 PM PT
Location:   Poster Section 45
Poster Board Number:   8
Published Abstract Number:   2548


The full poster will be posted to the company’s website in the Scientific Presentations & Publications page in the Investors section of the website shortly after the event.


About Notable Labs, Ltd.


Notable Labs, Ltd. is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable aims to predict whether or not a patient is likely to respond to a specific therapeutic. The PPMP platform is designed to identify and select clinically responsive patients prior to their treatment, potentially fast-tracking clinical development. By continually advancing and expanding the reach of the PPMP across diseases and predicted medical outcomes, Notable aims to be the leader in predictive precision medicine and revolutionize the way patients seek and receive treatments that work best for them.


Notable believes it has created a targeted and de-risked in-licensing strategy to deliver a product’s medical impact and commercial value faster, with a greater likelihood of success, than traditional drug development. By transforming historical standards of care, Notable aims to create a dramatically positive impact for patients and the healthcare community. Notable is headquartered in Foster City, California. Learn more at our website and follow us @notablelabs.





Forward Looking Statements


This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding Notable’s future operations and goals; the potential benefits of any therapeutic candidates or platform technologies of Notable; the timing of any clinical milestones of Notable’s therapeutic candidates; the cash runway of the company; and other statements that are not historical fact. All statements other than statements of historical fact contained in this communication are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and are based on the then-current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Notable’s control. Notable’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to (i) uncertainties associated with Notable’s platform technologies, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; (ii) risks related to the inability of Notable to obtain sufficient additional capital to continue to advance these product candidates and any preclinical programs; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (v) risks associated with Notable’s future financial and operating results, including its ability to become profitable; (vi) Notable’s ability to retain key personnel; (vii) Notable’s ability to manage the requirements of being a public company; (viii) uncertainties relating to the Israel-Hamas war; (ix) Notable’s ability to obtain orphan drug designation, and the associated benefits, for any of its drug candidates; (x) Notable’s inability to obtain regulatory approval for any of its drug candidates; and (xi) changes in, or additions to international, federal, state or local legislative requirements, such as changes in or additions to tax laws or rates, pharmaceutical regulations, and other regulations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission (“SEC”), including the factors described in the section titled “Risk Factors” in the Quarterly Report on Form 10-Q of Notable Labs, Ltd. as filed with the SEC on November 14, 2023, and in other subsequent filings with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Notable expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.




Investor Relations:

Daniel Ferry, LifeSci Advisors

+1 (617) 430-7576





GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 ntbl-20240408.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 ntbl-20240408_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 ntbl-20240408_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Apr. 08, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 08, 2024
Entity File Number 001-36581
Entity Registrant Name NOTABLE LABS, LTD.
Entity Central Index Key 0001603207
Entity Incorporation, State or Country Code L3
Entity Address, Address Line One 320 Hatch Drive
Entity Address, City or Town Foster City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94404
City Area Code (415)
Local Phone Number 851-2410
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary Shares, par value NIS 0.35 each
Trading Symbol NTBL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 21 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://notablelabs.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-60547-EntityTaxIdentificationNumber-Missing] Submission type 8-K should have a non-empty value for EntityTaxIdentificationNumber in the Required Context. form8-k.htm form8-k.htm ntbl-20240408.xsd ntbl-20240408_lab.xml ntbl-20240408_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "NTBL", "nsuri": "http://notablelabs.com/20240408", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "ntbl-20240408.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ntbl-20240408_lab.xml" ] }, "presentationLink": { "local": [ "ntbl-20240408_pre.xml" ] } }, "keyStandard": 21, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 21 }, "report": { "R1": { "role": "http://notablelabs.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001493152-24-013495-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-013495-xbrl.zip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end XML 19 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001603207 2024-04-08 2024-04-08 iso4217:USD shares iso4217:USD shares false 0001603207 8-K 2024-04-08 NOTABLE LABS, LTD. L3 001-36581 320 Hatch Drive Foster City CA 94404 (415) 851-2410 Ordinary Shares, par value NIS 0.35 each NTBL NASDAQ false false false false false